High dose right unilateral was as effective as bilateral electroconvulsive therapy for major depression


QUESTION: In patients with major depressive disorder (MDD), how do different dosages of right unilateral (RUL) electroconvulsive therapy (ECT) compare with high dosage bilateral (BL) ECT for antidepressant response and cognitive side effects?

Design
Randomised (allocation concealed†‡), blinded (patients and outcome assessors),* controlled trial with 1 week of follow up after the last ECT session.

Setting
New York State Psychiatric Institute, New York, USA.

Patients
84 patients (96% inpatients) who had MDD with a score of ≥18 on the 24-item Hamilton Rating Scale for Depression (HRSD). Exclusion criteria were history of functional psychosis or rapid cycling bipolar illness; neurological abnormality; substance abuse in the past year; ECT in the past 6 months; or severe medical illness. 80 patients (mean age 57 ± 64% women) completed the study.

Intervention
At the first ECT session patients’ seizure threshold (ST) was quantified and they were allocated to 1 of 4 groups with 20 patients each: RUL ECT with stimulus intensity at either 1.5 (low dose), 2.5 (moderate dose), or 5.0 (high dose); or BL ECT at 2.5 (high dose) times the initial ST.

Main outcome measures
Initial antidepressant response (decrease of ≥60% in HRSD scores and a score of ≤16 at 1 to 2 d after the last treatment). Final responders maintained response 1 week after the final treatment. Cognitive side effects were evaluated using anterograde and retrograde memory tests.

Main results
High dose RUL and BL ECT initial and final responder rates did not differ. Compared with BL ECT, fewer RUL ECT low and moderate dosage group patients had initial response (p = 0.002) (Table). Fewer RUL ECT group patients had final response than did BL ECT group patients (p = 0.03) (Table). Cognitive disturbance was greatest in the BL ECT group. The rates for disorientation immediately after treatment lasting >90 minutes and the extent of word recall or recognition were greatest with BL ECT than with any RUL ECT dosage (p = 0.002 and p = 0.03, respectively, for difference between BL ECT and all RUL ECT groups). 2–7 days after final treatment BL ECT resulted in greater impairment than any RUL ECT dosage on several cognitive measures. Cognitive differences persisted 2 months after completion of ECT.

Conclusion
In patients with major depression, markedly suprathereshold right unilateral electroconvulsive therapy (ECT) was as efficacious as high dose bilateral ECT for antidepressant response and had fewer cognitive side effects.

*See glossary.
†Information provided by author
‡Information provided by author

For correspondence: Dr H A Sackeim, Department of Biological Psychiatry, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. Fax +1 212 543 5854.

Right unilateral electroconvulsive therapy (RUL ECT) v bilateral (BL) ECT for antidepressant response in major depression

<table>
<thead>
<tr>
<th>Outcome time</th>
<th>Comparison</th>
<th>Rates</th>
<th>ABR (95% CI)</th>
<th>RBR (CI)</th>
<th>NNH (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 to 2 days (initial response)</td>
<td>Low dose RUL v BL ECT</td>
<td>35% v 80%</td>
<td>45% (14 to 68)</td>
<td>56% (22 to 78)</td>
<td>3 (2 to 8)</td>
</tr>
<tr>
<td></td>
<td>Moderate dose RUL v BL ECT</td>
<td>45% v 80%</td>
<td>35% (4.7 to 60)</td>
<td>44% (7.9 to 69)</td>
<td>3 (2 to 20)</td>
</tr>
<tr>
<td></td>
<td>High dose RUL v BL ECT</td>
<td>80% v 80%</td>
<td>0% (−26 to 26)</td>
<td>0% Not significant</td>
<td></td>
</tr>
<tr>
<td>1 week (final response)</td>
<td>Low dose RUL v BL ECT</td>
<td>35% v 65%</td>
<td>30% (1.4 to 56)</td>
<td>46% (−2 to 74)</td>
<td>Not significant</td>
</tr>
<tr>
<td></td>
<td>Moderate dose RUL v BL ECT</td>
<td>30% v 65%</td>
<td>35% (3.7 to 60)</td>
<td>54% (8.1 to 79)</td>
<td>3 (2 to 25)</td>
</tr>
<tr>
<td></td>
<td>High dose RUL v BL ECT</td>
<td>65% v 65%</td>
<td>0% (−29 to 29)</td>
<td>0% Not significant</td>
<td></td>
</tr>
</tbody>
</table>

†ABR=absolute benefit reduction; RBR=relative benefit reduction. Other abbreviations defined in glossary; ABR, RBR, NNH, and CI calculated from data in article.

COMMENTARY—continued from previous page

McCall et al compared titrated moderately suprathereshold with fixed high dose RUL ECT. Previously published trials have reported RUL ECT efficacy and memory effects to be sensitive to stimulus dosing above ST. McCall et al confirmed these findings in their study as retrospective analysis of the fixed high dose RUL ECT group showed that treatments at dosage intensities from 3.15 to 5.04 times ST were much less effective than those at intensities from 8.4 to 12.6 times ST. Differences detected in adverse effects were apparent 1–2 days after the ECT course at a dosage of 3.15 to 5.04 times ST, but were dramatically worsened at a dosage of 8.4 to 12.6 times ST. Such worsening effects on immediate memory paralleled improvement in antidepressant efficacy. As with the results of the study by Sackeim et al, clinicians will have to balance the antidepressant benefit of high dose RUL ECT against increased memory impairment.

The BL v RUL ECT controversy remains unresolved. Readers should be cautious about adopting a recommendation for RUL ECT at 6 times ST in their clinical practice, even for depressed patients. Short term cognitive side effects are less likely, but problems with small sample size and choice of BL ECT dosage intensity in the study by Sackeim et al mean that important clinical questions remain about their comparative efficacy. The results from McCall et al suggest that, as assessed, RUL ECT is too inefficient for routine use and the reduced memory impairment is of limited clinical significance. My recommendation for practitioners is that BL ECT at 1.5 times the estimated or measured ST remains the clinical standard.

Max Fink, MD
State University New York at Stony Brook
Long Island, New York, USA

High dose right unilateral was as effective as bilateral electroconvulsive therapy for major depression

Evid Based Mental Health 2000 3: 115
doi: 10.1136/ebmh.3.4.115

Updated information and services can be found at:
http://ebmh.bmj.com/content/3/4/115

These include:

References
This article cites 2 articles, 0 of which you can access for free at:
http://ebmh.bmj.com/content/3/4/115#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: psychiatry (344)
- Depressive disorder (570)
- Neurology (1070)
- Substance dependence (407)
- Clinical trials (epidemiology) (989)
- Epidemiology (1570)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/